These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 22519451)

  • 21. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG
    Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Matrix metalloproteinases and their tissue inhibitors].
    Trojanek J
    Postepy Biochem; 2012; 58(3):353-62. PubMed ID: 23373420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinases: a therapeutic target in cardiovascular disease.
    Sierevogel MJ; Pasterkamp G; de Kleijn DP; Strauss BH
    Curr Pharm Des; 2003; 9(13):1033-40. PubMed ID: 12678855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors.
    Spinale FG; Villarreal F
    Biochem Pharmacol; 2014 Jul; 90(1):7-15. PubMed ID: 24780447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix Metalloproteinases in Kidney Disease: Role in Pathogenesis and Potential as a Therapeutic Target.
    Parrish AR
    Prog Mol Biol Transl Sci; 2017; 148():31-65. PubMed ID: 28662825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac remodeling and failure From molecules to man (Part II).
    Fedak PW; Verma S; Weisel RD; Li RK
    Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
    Liu J; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
    Wilson EM; Spinale FG
    Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY; Feldman AM
    Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinases and coronary artery diseases.
    Ikeda U; Shimada K
    Clin Cardiol; 2003 Feb; 26(2):55-9. PubMed ID: 12625594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
    Galis ZS; Sukhova GK; Lark MW; Libby P
    J Clin Invest; 1994 Dec; 94(6):2493-503. PubMed ID: 7989608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinases: pathways of induction by bioactive molecules.
    Tsuruda T; Costello-Boerrigter LC; Burnett JC
    Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
    Maskos K; Bode W
    Mol Biotechnol; 2003 Nov; 25(3):241-66. PubMed ID: 14668538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
    Lizotte-Waniewski M; Brew K; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase inhibition and the prevention of heart failure.
    Lee RT
    Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
    Hoffmann U; Brueckmann M; Borggrefe M
    Crit Care; 2009; 13(6):1006. PubMed ID: 20017890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
    Narula S; Tandon C; Tandon S
    Curr Med Chem; 2018; 25(15):1805-1816. PubMed ID: 29210632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.
    Moore L; Fan D; Basu R; Kandalam V; Kassiri Z
    Heart Fail Rev; 2012 Sep; 17(4-5):693-706. PubMed ID: 21717224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metalloproteinase inhibitors: biological actions and therapeutic opportunities.
    Baker AH; Edwards DR; Murphy G
    J Cell Sci; 2002 Oct; 115(Pt 19):3719-27. PubMed ID: 12235282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and Biological Attributes of Matrix Metalloproteinases.
    Cui N; Hu M; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.